Enrollment data

That's why the stockholders need specific numbers on a regular basis. The number of patients enrolled in CD12 is the company's single most important metric with respect to the stock price at this point. If the number keeps going up at a reasonable pace, and you believe in the drug as I do, you are bullish. If you don't know if the progress is reasonable, you're bearish, no matter what your trust in the science is. If you've been holding the stock for a while, you will notice that the stock tends to drop in price when there is an information vacuum. Truthful information, even if not the best news, prevents the vacuum and raises corporate credibility. When the vacuum exists, people think the worst and sell.

CYDY can stay ahead of the field if the enrollment moves along. Most of us stockholders think the drug works. The question is what the competition will be when it gets its release. If the enrollment moves along, we'll stand alone for a while and will sell out the drug at a high price. If the enrollment stalls and others catch up, we could be dead in the water or, at best, in the middle of a dogfight. Some of our competitors have good profiles, even if I think ours is better.

Send CYDY a message on their website. We need to keep management's feet to the fire. We also need to know where we stand. Finally, we also need a higher stock price. Good enrollment means we'll be where we need to be.
.